Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

FAIR VALUE (Details)

FAIR VALUE (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Fair Value
Investments at fair value	$ 38,368	$ 47,787
Fair Value Measurements Recurring \| Estimate Of Fair Value Fair Value Disclosure
Fair Value
Investments at fair value	55,542	51,942
Fair Value Measurements Recurring \| Money market funds \| Estimate Of Fair Value Fair Value Disclosure
Fair Value
Investments at fair value	17,174	4,155
Fair Value Measurements Recurring \| US treasury bills \| Estimate Of Fair Value Fair Value Disclosure
Fair Value
Investments at fair value		5,225
Fair Value Measurements Recurring \| Government-sponsored enterprise securities \| Estimate Of Fair Value Fair Value Disclosure
Fair Value
Investments at fair value	25,442	15,796
Fair Value Measurements Recurring \| Corporate bonds and commercial paper \| Estimate Of Fair Value Fair Value Disclosure
Fair Value
Investments at fair value	12,926	26,766
Fair Value Measurements Recurring \| Level 1
Fair Value
Investments at fair value	17,174	4,155
Fair Value Measurements Recurring \| Level 1 \| Money market funds
Fair Value
Investments at fair value	17,174	4,155
Fair Value Measurements Recurring \| Level 2
Fair Value
Investments at fair value	38,368	47,787
Fair Value Measurements Recurring \| Level 2 \| US treasury bills
Fair Value
Investments at fair value		5,225
Fair Value Measurements Recurring \| Level 2 \| Government-sponsored enterprise securities
Fair Value
Investments at fair value	25,442	15,796
Fair Value Measurements Recurring \| Level 2 \| Corporate bonds and commercial paper
Fair Value
Investments at fair value	$ 12,926	$ 26,766